PLRX
NASDAQPliant Therapeutics Inc.
Price$1.16-0.03 (-2.52%)
01:30 PM07:45 PM
News · 26 weeks41-50%
2025-12-072026-05-31
Mix2390d
- SEC Filings11(48%)
- Other6(26%)
- Insider4(17%)
- Leadership2(9%)
Latest news
25 items- PRPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingHighlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter:Timothy A. Yap, MBBS, Ph.D., Univer
- PRAtisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the BoardRB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Dire
- SECSEC Form 10-Q filed by Pliant Therapeutics Inc.10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECPliant Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- PRPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsFirst participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported first quarter 2026 financial results. "In the first quarter, our team showcas
- PRPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D., Pliant's Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time. Interested parties may access the live webcast of the RBC fireside chat by visiting the Investor Relations' Events & Presentation page of Pliant's website. The
- PRPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsSOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1. "We are pleased to announce this milestone for the FORTIFY trial and the expansion into solid tumor cohorts that we believe are supported by PLN-101095's mechanism of action," said Bernard Coulie, M.D., Ph.D.., Chief Executive Offic
- SECSEC Form DEFA14A filed by Pliant Therapeutics Inc.DEFA14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECSEC Form DEF 14A filed by Pliant Therapeutics Inc.DEF 14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- PRPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingConfirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR's Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif., April 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association f
- INSIDERSEC Form 4 filed by Kuo Minnie4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
- INSIDERSEC Form 4 filed by Cummings Keith Lamont4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
- INSIDERSEC Form 4 filed by Coulie Bernard4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
- INSIDERSEC Form 4 filed by Cheung Lily4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
- SECPliant Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECSEC Form EFFECT filed by Pliant Therapeutics Inc.EFFECT - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECSEC Form S-3 filed by Pliant Therapeutics Inc.S-3 - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECPliant Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- PRPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingSOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title: First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembr
- SECSEC Form 10-K filed by Pliant Therapeutics Inc.10-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECSEC Form 8-K filed by Pliant Therapeutics Inc.8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- SECSEC Form S-8 filed by Pliant Therapeutics Inc.S-8 - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- PRPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsPLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. "We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated
- SECPliant Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
- PRPliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations' Ev
PLRX FAQ
7 questionsWhat does Pliant Therapeutics Inc. do?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective...Where does PLRX stock trade?
Pliant Therapeutics Inc. (PLRX) is listed on NASDAQ.What sector and industry is PLRX in?
Pliant Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pliant Therapeutics Inc. go public?
Pliant Therapeutics Inc. (PLRX) completed its IPO in 2020.What are analysts saying about PLRX?
Pliant Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight on 2025-10-10. Recent price targets cluster around $400.00.What companies are similar to PLRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PLRX side-by-side with any of them on Quantisnow.How can I track PLRX on Quantisnow?
Quantisnow aggregates Pliant Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLRX to receive live email and push alerts on every new disclosure.